Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

Tai Tien Pharmaceuticals

Status and phase

Unknown

Phase 3

Conditions

Hyperlipidemia

Treatments

Drug: Atorvastatin

Drug: Pitavastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT01386853

TATPITA20101005

Details and patient eligibility

About

This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.

Enrollment

200 estimated patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient aged ≥ 20 years old and < 75 years old.
Patient who was eligible and able to participate in the study and accepts to enter the study by signing written informed consent.
Patient with fasting LDL-C > 100 mg/dL. The concentration of LDL-C is obtained from laboratory examination.
Patient with at least one of the following description (NCEP ATP III guideline).
Female patient with child-bearing potential must take reliable contraception method(s) during the participation of the study.

Exclusion criteria

Patient who has participated in other investigational studies within 3 months.
Patient took medication and natural health foods known to alter blood lipid profiles within 4 weeks.
Patient is taking any medication or food that is prohibited by the study.
Patient taking Amiodarone will be excluded from this study (due to long half life of this medication).
Patient is diagnosed with type 1 DM or has been using insulin/insulin analog medication.
Patient with a history of multiple drug allergies or with a known allergy to HMG-CoA reductase inhibitors.
Patient with TG > 400 mg/dL.
Excessive obesity defined as BMI above 35 kg/m2.
Cerebral vascular disease (including cerebrovascular hemorrhage or ischemia, transient ischemic attack) diagnosed within 3 months.
Myocardial infarction, heart failure (NYHA class III or IV), gross cardiac enlargement (cardiothoracic ratio > 0.5), significant heart block or cardiac arrhythmias within 3 months; history of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardia, pacemaker or implantable cardiac device were not eligible for this study.
Patient with advanced renal disorder (Serum creatinine levels ≥ 2 mg/dL and BUN ≥ 25 mg/dL).
Patient with advanced hepatic disorder (AST or ALT level ≥ 100 IU/L)
Patient with CK level > 5 × ULRR at any time point between Visit 1 and Visit 2.
Patient with poorly controlled diabetes mellitus (HbA1c > 9.0%) or patient with severe hypertension (> 180 mmHg for systolic or > 120 mmHg in diastolic blood pressure).
Patient with hypothyroidism, hereditary muscular disorders, family history of the above or history of drug-induced myopathy.
Patient has significant alcohol consumption (> 65 mL pure alcohol) within 48 hours before Visit 2.
Any major surgery within 3 months prior to Visit 2.
Female patient who is lactating, being pregnant or plans to become pregnant.
Patient with conditions judged by the investigator as unsuitable for the study.